Skip to Main Content

Paper Details

A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.
Oncologist
45
2019
BEV, Bevacizumab, CCNU, Glioblastoma, PATIENTS, PD1, Recurrent, TAMIGA, bevacizumab, glioblastoma, lomustine, patients, recurrent glioblastoma, temozolomide
Author NameAffiliation
Warren P MasonCancer Clinical Research Unit, Princess Margaret Cancer Centre
Gaetano FinocchiaroIstituto Neurologico Carlo Besta
Gaetano FinocchiaroIstituto Neurologico Carlo Besta
Josef PichlerInstitut fur Innere Medizin mit Neuroonkologie
  • 1 - 4

Datasets

Release 1.2